These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29915627)

  • 1. Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.
    Zhou W; Huang Y; Lai J; Lu J; Feely M; Liu X
    Gastroenterology Res; 2018 Jun; 11(3):174-188. PubMed ID: 29915627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal injury induced by immunomodulators: A review article.
    Zhang P; Mao R; Zhang C; Qiu Y; Chen M
    Therap Adv Gastroenterol; 2023; 16():17562848231158549. PubMed ID: 37113189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2005; 5(1):10-8. PubMed ID: 15741928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colitis associated with biological agents.
    Freeman HJ
    World J Gastroenterol; 2012 Apr; 18(16):1871-4. PubMed ID: 22563166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in biologic therapy for ulcerative colitis and Crohn's disease.
    D'Haens G; Daperno M
    Curr Gastroenterol Rep; 2006 Dec; 8(6):506-12. PubMed ID: 17105690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic problems and advances in inflammatory bowel disease.
    Odze R
    Mod Pathol; 2003 Apr; 16(4):347-58. PubMed ID: 12692200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies.
    Peyrin-Biroulet L; Demarest S; Nirula A
    Autoimmun Rev; 2019 Feb; 18(2):123-128. PubMed ID: 30572136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for targeting tumour necrosis factor in IBD.
    Sandborn WJ
    Best Pract Res Clin Gastroenterol; 2003 Feb; 17(1):105-17. PubMed ID: 12617886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.
    Ha C; Kornbluth A
    Gastroenterol Hepatol (N Y); 2014 Dec; 10(12):793-800. PubMed ID: 27524947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of anti-TNF therapy (biologics) in the treatment of chronic inflammatory bowel disease in children].
    Kolacek S
    Acta Med Croatica; 2013 Apr; 67(2):89-92. PubMed ID: 24471292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Shivaji UN; Sharratt CL; Thomas T; Smith SCL; Iacucci M; Moran GW; Ghosh S; Bhala N
    Aliment Pharmacol Ther; 2019 Mar; 49(6):664-680. PubMed ID: 30735257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapies in inflammatory bowel disease.
    Cohen LB; Nanau RM; Delzor F; Neuman MG
    Transl Res; 2014 Jun; 163(6):533-56. PubMed ID: 24467968
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.